Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Lymphoma 93Leukemia 63Burkitt Lymphoma 57Lymphoma, Non-Hodgkin 50Lymphoma, Large B-Cell, Diffuse 44Lymphoma, Mantle-Cell 38Lymphoma, Follicular 30Recurrence 29Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Lymphocytic, Chronic, B-Cell 26Multiple Myeloma 21Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Leukemia, Biphenotypic, Acute 16Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, B-Cell 13Leukemia, Myeloid, Acute 13Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, T-Cell, Peripheral 10Neoplasms 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, T-Cell, Cutaneous 8Lymphoma, T-Cell 7Intraocular Lymphoma 6Hematologic Neoplasms 6Blast Crisis 6Sezary Syndrome 5

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Dexamethasone × Lymphoid × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡